Literature DB >> 26216447

Comparative functional selectivity of imidafenacin and propiverine, antimuscarinic agents, for the urinary bladder over colon in conscious rats.

Yukiko Muraki1.   

Abstract

Antimuscarinics are the first-line choice of treatment for overactive bladder (OAB). Imidafenacin distributes in the bladder more selectively than in the submaxillary gland and colon, and hence, this drug is considered more useful for OAB than other antimuscarinics. However, the examination of imidafenacin selectivity to bladder over colon using in vivo models is limited. Thus, the author examined whether imidafenacin could induce more selective blockade of the bladder over colon in conscious rats using two pharmacological indices (colonic transit and neostigmine-induced fecal pellet output) and compared its bladder selectivity with propiverine. In the bladder study, the inhibitory doses of antimuscarinics were calculated using the area under the curve of the distension-induced rhythmic contraction in conscious rats. The relative bladder selectivity of imidafenacin to propiverine was 50-fold and 61-fold, respectively, in a dye marker colonic transit model and in a neostigmine-induced fecal pellet output model. This comparative study shows that the functional bladder selectivity of imidafenacin is higher than that of propiverine tested under the present conditions in conscious rats.

Entities:  

Keywords:  Antimuscarinics; Bladder selectivity; Colonic transit; Conscious rat; Imidafenacin; Overactive bladder

Mesh:

Substances:

Year:  2015        PMID: 26216447     DOI: 10.1007/s00210-015-1155-9

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  39 in total

Review 1.  Therapeutic opportunities from muscarinic receptor research.

Authors:  R M Eglen; A Choppin; N Watson
Journal:  Trends Pharmacol Sci       Date:  2001-08       Impact factor: 14.819

Review 2.  The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society.

Authors:  Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip Van Kerrebroeck; Arne Victor; Alan Wein
Journal:  Urology       Date:  2003-01       Impact factor: 2.649

3.  Urothelial/lamina propria spontaneous activity and the role of M3 muscarinic receptors in mediating rate responses to stretch and carbachol.

Authors:  Christian Moro; Jumpei Uchiyama; Russ Chess-Williams
Journal:  Urology       Date:  2011-10-15       Impact factor: 2.649

4.  Muscarinic and 5-HT4 receptors participate in the regulation of the frequency of spontaneous contractions of the longitudinal muscle in rat distal colon.

Authors:  Shigeyuki Ono; Retsu Mitsui; Shin-ichiro Karaki; Atsukazu Kuwahara
Journal:  Biomed Res       Date:  2005-08       Impact factor: 1.203

5.  Identification of atropine- and P2X1 receptor antagonist-resistant, neurogenic contractions of the urinary bladder.

Authors:  Charles Kennedy; Paul N Tasker; Gemma Gallacher; Timothy D Westfall
Journal:  J Neurosci       Date:  2007-01-24       Impact factor: 6.167

6.  Interactions between cholinergic and prostaglandin signaling elements in the urothelium: role for muscarinic type 2 receptors.

Authors:  C J Nile; J I Gillespie
Journal:  Urology       Date:  2011-11-04       Impact factor: 2.649

7.  Evidence for the presynaptic action of 5-hydroxytryptamine and the involvement of purinergic innervation in the rabbit lower urinary tract.

Authors:  H I Chen
Journal:  Br J Pharmacol       Date:  1990-09       Impact factor: 8.739

Review 8.  Selective β₃-adrenoceptor agonists for the treatment of overactive bladder.

Authors:  Karl-Erik Andersson; Nancy Martin; Victor Nitti
Journal:  J Urol       Date:  2013-02-28       Impact factor: 7.450

Review 9.  Muscarinic receptor antagonists for overactive bladder.

Authors:  Paul Abrams; Karl-Erik Andersson
Journal:  BJU Int       Date:  2007-11       Impact factor: 5.588

10.  Absolute bioavailability of imidafenacin after oral administration to healthy subjects.

Authors:  Tomoya Ohno; Susumu Nakade; Kazuki Nakayama; Junsaku Kitagawa; Shinya Ueda; Hiroyuki Miyabe; Yuichi Masuda; Yasuyuki Miyata
Journal:  Br J Clin Pharmacol       Date:  2008-02       Impact factor: 4.335

View more
  1 in total

1.  Predicted Biological Activity of Purchasable Chemical Space.

Authors:  John J Irwin; Garrett Gaskins; Teague Sterling; Michael M Mysinger; Michael J Keiser
Journal:  J Chem Inf Model       Date:  2017-12-29       Impact factor: 4.956

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.